INTRODUCTION
Multiple sclerosis (MS) is a debilitating disease, which is estimated to affect *5,000 people in Portugal based on the crude prevalence of MS (46.3/100,000 inhabitants) found in the sole published study [1] . Despite the availability of different disease-modifying therapies (DMTs) to slow the progression of disability and reduce relapse rates of relapsing-remitting MS (RRMS), these therapies only show moderate effectiveness and in most patients the disease progresses [2] [3] [4] . Approximately, 62-75% of patients relapse after 2 years of disease and 20-27% have an increase in their disability of at least one point in the Expanded Disability Status Scale (EDSS) [5] [6] [7] [8] [9] . Close monitoring of response to first-line DMTs becomes important in identifying patients with sub-optimal response to improve treatment strategies and better control disease.
Therapeutic response is based on the evaluation of relapse rates, disability (as measured by EDSS) and magnetic resonance imaging (MRI) [10] [11] [12] . Relapse is a good indicator of clinical disease activity, however, its use as an isolated measure is controversial [10] . Changes in EDSS alone must also be regularly confirmed to overcome possible false or transient values associated with relapses or other medical conditions [10] . MRI has a high additional value in monitoring response to therapy, since inflammatory events occur more frequently than clinical events [13] , but its usefulness per se in monitoring treatment response is not well established [10] . Several treatment response criteria based on these parameters have been proposed [14] [15] [16] [17] [18] , although many were not validated over longterm follow-up periods [10] , but there is no consensus about the best [10, 19] . Despite the lack of consensus, the potential of combining clinical (relapse rate and disability progression) and MRI measures, for predicting disease progression and monitoring treatment response, has been recognized [20] . 
Participants and Eligibility Criteria
Patients with RRMS treated for at least 1 year with one specific DMT in the 12 months prior to questionnaire completion. The diagnostic criteria used for RRMS were those developed before 2008 (from Poser et al. [21] or McDonald et al. [22] , depending on the year of diagnosis).
Data Collected in Questionnaire
The following data were captured in the questionnaire-patient characteristics: age, gender, and date of RRMS diagnosis; first-line DMT in the 12 months prior to the date of questionnaire completion (''study period''); whether the patient received such therapy or not, and if 'yes', the start and stop dates or if treatment was ongoing; and clinical disease history: disability assessed by the EDSS 12 months prior to the date of completion of the questionnaire (defined as baseline EDSS), number and date of any relapses in the prior 12 months, and disease duration.
The following were considered first-line therapies: interferon beta-1a intramuscular (IFNb-1a IM), interferon beta-1b subcutaneous (IFNb-1b SC), interferon beta-1a 22 lg SC (IFNb-1a 22 lg SC), interferon beta-1a 44 lg SC (IFNb-1a 44 lg SC), and glatiramer acetate SC (GA).
EDSS scores were collected from patient medical files. No estimations were allowed and so patients were excluded if any data were missing. EDSS scoring was performed by the treating MS neurologist. Neutralizing antibody testing was not undertaken as it is not routine clinical practice in Portugal.
Disability Assessment at Time
Questionnaire Completed EDSS was also assessed by the site neurologist at time the questionnaire was completed, allowing the measure of patient disability at the end of 12-month treatment.
Treatment Response Criteria
The treatment response criteria were the optimal and sub-optimal clinical responses. A sub-optimal clinical response was defined as occurring in patients receiving DMT for C1 year with one or more relapses, or patients treated with DMTs for C1 year with an increase by C1.5 points in EDSS (if baseline EDSS was 0), or by C0.5 points (if baseline EDSS was C1). An optimal clinical response was seen in patients treated with DMT for C1 year without relapses and, simultaneously, with an increase of \1.5 points in EDSS (if baseline EDSS was 0), or no increase in EDSS (if baseline EDSS was C1).
Study Size
The planned sample size was 1,200 patients with RRMS, representing *35% of patients on treatment with DMTs in Portugal at the time [23] .
Statistical Methods
Demographic and clinical characteristics of patients were analyzed through descriptive statistics and compared among therapies using one-way analysis of variance (ANOVA) or Fisher Exact tests for continuous or categorical variables, respectively. The non-parametric Kruskal-Wallis test was used to confirm the results obtained from ANOVA for variables with skewed distributions. Scheffé tests were used to determine which pairs of means were statistically different if ANOVA results were statistically significant.
Patients' sociodemographic characteristics were also compared between those with optimal and sub-optimal responses using two-sided t tests or Mann-Whitney tests for normally and nonnormally distributed variables, respectively.
Fisher Exact tests were used to assess the association between the various therapies and the type of response (sub-optimal vs. optimal). 
RESULTS
Fifteen of the 20 invited neurology centers entered the study. Five centers were large, five were medium, and five were small. The remaining centers did not collect any patient data during the data collection period.
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Socio-Demographic and Clinical Factors
Differences between treatment groups in sociodemographic and clinical characteristics are presented in Table 3 . Duration of therapy, age at the start of therapy, and baseline EDSS differed significantly among treatments.
Patients treated with GA had a significantly lower duration of therapy and were older than patients treated with other therapies. Baseline EDSS was significantly lower in patients treated with IFNb-1a IM and IFNb-1a 22 lg SC when compared with patients treated with other therapies.
Patterns of Treatment Response
Twenty-six percent (95% CI 23-28%) of patients had sub-optimal response to treatment. The mean number of relapses, and baseline EDSS for the optimal responders were 0.0 and 2.0, respectively, and for the sub-optimal responders were 1.0 and 2.6, respectively. Percentages of sub-optimal and optimal responses by DMT are presented in Fig. 1 .
Treatment with IFNb-1a 44 lg SC for 12 months appeared to be associated with a greater proportion of sub-optimal responses compared with the other therapies, in (Tables 3, 4 ); however, multiple logistic regression analysis showed that only EDSS at baseline was associated with a sub-optimal response to therapy (Table 4 ).
Age, duration of therapy, gender, disease duration did not appear to influence response.
DISCUSSION
The purpose of this survey was to characterize treatment response to first-line DMTs in RRMS patients in Portugal, and to identify the factors associated with treatment response. Our study was designed based on a retrospective multicenter study in Germany that included 461 centers and 8,275 patients [24] . The results of our study are in line with the previously mentioned German study. They showed that, despite treatment with DMTs, 20% of RRMS patients had relapses over a 12-month period, and 26% had sub-optimal treatment response. The proportion of patients with sub-optimal response was associated with worse baseline EDSS scores, and no differences in response were observed among therapies. A considerably high proportion of patients had one or more relapses (20%) indicating low disease control [25] . Results from previous studies showed that patients who present with any two of clinical disease activity, disease progression, or MRI activity after 12 months of therapy with IFNb, are potentially eligible to switch therapies since the risk for disease progression is higher in subsequent years [10, 26] .
The efficacy results shown in this study are consistent with an Italian independent study that found no between-treatment differences in the proportion of relapse-free patients and EDSS score changes at 12 months, in a cohort of 540 RRMS patients treated with different IFNb therapies [27] . Furthermore, similar results were shown in another smaller retrospective cohort of 134 RRMS patients from Argentina, treated with IFNb and GA for 16 months [28] .
Although we found a higher percentage of relapse-free patients in patients receiving any IFNb, GA relapse-free patient data in the Argentinian study is in line with this study.
Similar to our results, Carrá et al. [28] did not find a significant reduction in EDSS scores in any of the treatment groups. Variability between baseline disease activity and treatment duration in each study population may explain such differences.
There is no consensus about the definition of optimal or sub-optimal response, but Rio et al.
[15] evaluated the influence of different definitions on the treatment response to IFNb treatment. The definition closest to ours considered the presence of one or more relapses, and an increase of 1.5 points for a baseline EDSS of 0 (1 point for EDSS between 1.0 and 5.0, and 0.5 points for EDSS C5.5) [15] . The number of relapses in the optimal responders group was similar to our study, but in the suboptimal responders group, the average relapse rate was higher in the study of Rio et al. [15] .This difference in relapse rate between studies may be due not only to the different Fig. 1 Percentage of sub-optimal and optimal responses by disease-modifying therapy. GA Glatiramer acetate, IFN interferon, IM intramuscular, SC subcutaneous definitions used for optimal and sub-optimal responder, but also to the duration of follow-up (2-year vs. 1-year follow-up in our study). In view of these results, it seems that treatment efficacy depends largely on the definition of response applied [15] . Indeed, in the literature, 
CONCLUSION
This study makes an important contribution to the identification of types of treatment responses in patients with RRMS in Portugal, implemented when it is still expected that other drugs are effective [7] . Our study draws attention to the fact that no major differences in type of response were found between treatments, but that all have a considerably high proportion of sub-optimal responses. The ability to identify patients with optimal or suboptimal response to treatment is therefore important in that it may assist in the decision of what treatment to use and on the possibility of changing it.
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